ADRD - Invesco BLDRS Developed Markets 100 ADR Index Fund

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
20.52
+0.18 (+0.91%)
At close: 3:03PM EDT
Stock chart is not supported by your current browser
Previous Close20.33
Open20.49
Bid20.45 x 1000
Ask20.53 x 1200
Day's Range20.49 - 20.52
52 Week Range18.87 - 22.80
Volume557
Avg. Volume4,065
Net Assets31.9M
NAV20.39
PE Ratio (TTM)N/A
Yield3.82%
YTD Return6.05%
Beta (3Y Monthly)0.94
Expense Ratio (net)0.30%
Inception Date2002-11-13
Trade prices are not sourced from all markets
  • Sanofi’s Q3 Earnings: Analysts’ Estimates
    Market Realist

    Sanofi’s Q3 Earnings: Analysts’ Estimates

    Sanofi (SNY) is one of the largest pharmaceutical companies. Since the company’s headquarters are in Paris, its reports its financial results in euros. Sanofi is set to release its third-quarter earnings on October 31. Wall Street analysts expect the EPS to be 1.71 euros on revenues of 9.32 billion euros during the third quarter.

  • How Novartis’s Alcon Performed in Third Quarter
    Market Realist

    How Novartis’s Alcon Performed in Third Quarter

    Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.

  • How Novartis’s Business Segments Performed in the Third Quarter
    Market Realist

    How Novartis’s Business Segments Performed in the Third Quarter

    As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017. 

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • How Novartis’s Businesses Have Been Performing
    Market Realist

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
    Market Realist

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.

  • How GlaxoSmithKline’s Vaccines Business Has Performed Recently
    Market Realist

    How GlaxoSmithKline’s Vaccines Business Has Performed Recently

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.

  • Novartis’s Key Developments in August
    Market Realist

    Novartis’s Key Developments in August

    As we’ve already seen, Novartis (NVS) reported a 7% growth YoY (year-over-year) in revenues to ~$13.16 billion during Q2 2018.

  • Novartis’s Innovative Medicines Business in Q2 2018
    Market Realist

    Novartis’s Innovative Medicines Business in Q2 2018

    As we’ve already seen, Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. Innovative Medicines contributed ~67.4% of Novartis’s total revenues in Q2 2018, a 10% growth YoY (year-over-year) to $8.9 billion.